Established in August 2019 in Shenzhen, China, Evergreen Therapeutics is an international, innovative, clinical-stage pharmaceutical company. It is committed to meeting the clinical needs and achieving medical value to benefit patients worldwide. Headquartered in Shenzhen, Evergreen has office and laboratory in the United States. Established for more than two years, Evergreen has developed rapidly and has become a leader in efficient R&D of Chinese innovative pharmaceutical enterprise and a pioneer in internationalization of Chinese innovative pharmaceutical enterprise.
Evergreen applies artificial intelligence (AI) and has always adhered to a global and differentiated development strategy, focusing on the research and development of innovative drugs in the fields of autoimmunity, tumor immunity, chronic diseases, ophthalmology, etc. While exploring new targets, the company also actively develops new indications for existing drugs. At present, the company has 90 authorized patents and 12 product pipelines, and has been granted for 17 patents. Five drugs have entered clinical stage. The patents cover major global pharmaceutical markets such as China, theUnited States, Europe, and Japan. Several drugs are in the pipeline, ranging from treatment or COVID-19, age-related macular degeneration, idiopathic interstitial pneumonia, and dry eye; the market for these drugs looks promising.
Evergreen was founded by highly experienced pharmaceutical executives. Nearly all of senior management and R&D team members have experiences in the US FDA or at top international pharmaceutical companies. The advisory team also consists of world's top experts. While the company is constantly improving its internal research and development capabilities, the management team is also actively planning and hosting highly recognized,international medical conferences to discuss and promote new drug development and innovation in the pharmaceutical industry.
With dual headquarters in Shenzhen, China, and Maryland, USA, Evergreen actively engages in international exchanges and investor communication while taking advantage of its location in the Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone.
Established in August 2019 in Shenzhen, China, Evergreen Therapeutics is an international, innovative, clinical-stage pharmaceutical company. It is committed to meeting the clinical needs and achieving medical value to benefit patients worldwide. Headquartered in Shenzhen, Evergreen has office and laboratory in the United States. Established for more than two years, Evergreen has developed rapidly and has become a leader in efficient R&D of Chinese innovative pharmaceutical enterprise and a pioneer in internationalization of Chinese innovative pharmaceutical enterprise.
Evergreen applies artificial intelligence (AI) and has always adhered to a global and differentiated development strategy, focusing on the research and development of innovative drugs in the fields of autoimmunity, tumor immunity, chronic diseases, ophthalmology, etc. While exploring new targets, the company also actively develops new indications for existing drugs. At present, the company has 90 authorized patents and 12 product pipelines, and has been granted for 17 patents. Five drugs have entered clinical stage. The patents cover major global pharmaceutical markets such as China, theUnited States, Europe, and Japan. Several drugs are in the pipeline, ranging from treatment or COVID-19, age-related macular degeneration, idiopathic interstitial pneumonia, and dry eye; the market for these drugs looks promising.
Evergreen was founded by highly experienced pharmaceutical executives. Nearly all of senior management and R&D team members have experiences in the US FDA or at top international pharmaceutical companies. The advisory team also consists of world's top experts. While the company is constantly improving its internal research and development capabilities, the management team is also actively planning and hosting highly recognized,international medical conferences to discuss and promote new drug development and innovation in the pharmaceutical industry.
With dual headquarters in Shenzhen, China, and Maryland, USA, Evergreen actively engages in international exchanges and investor communication while taking advantage of its location in the Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone.